Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $6.00. Emily Bodnar’s rating is based on ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ventyx Biosciences (NASDAQ:VTYX) files prospectus the offer and resale from time to time of up to 7,060,100 shares of common stock. SEC Filing More on Ventyx Biosciences Ventyx Biosciences: R ...

Biotech and pharma stocks such as Apellis Pharmaceuticals, Ventyx Biosciences, and BridgeBio Pharma also dragged on performance. Based on our assessment of the fund’s People, Process ...

At close: November 7 at 4:00 PM EST ...

China Shineway Pharmaceutical Group Ltd.-16.08% +0.00% China Shineway Pharmaceutical Group Ltd. +0.00% +0.00% ...

Revenue in Q3 2024 decreased by $3.8 million to $61.6 million as compared to $65.4 million in Q3 2023. The year-over-year decrease in revenue can primarily be attributed to a decrease in retail ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and ...

On Tuesday, H.C. Wainwright adjusted its outlook on Caribou Biosciences Inc. (NASDAQ:CRBU), increasing the price target to $24 from the previous $23 while maintaining a Buy rating ...